CU20160156A7 - Compuestos de isoquinolinas 2-sustituidas o sus análogos que poseen hasta cinco átomos de carbono sustituidos por nitrógeno,útiles como ligandos de dopamina d1 - Google Patents

Compuestos de isoquinolinas 2-sustituidas o sus análogos que poseen hasta cinco átomos de carbono sustituidos por nitrógeno,útiles como ligandos de dopamina d1

Info

Publication number
CU20160156A7
CU20160156A7 CUP2016000156A CU20160156A CU20160156A7 CU 20160156 A7 CU20160156 A7 CU 20160156A7 CU P2016000156 A CUP2016000156 A CU P2016000156A CU 20160156 A CU20160156 A CU 20160156A CU 20160156 A7 CU20160156 A7 CU 20160156A7
Authority
CU
Cuba
Prior art keywords
digamin
attitudes
dopamine
analogs
nitrogen
Prior art date
Application number
CUP2016000156A
Other languages
English (en)
Spanish (es)
Inventor
David Lawrence Firman Gray
Lei Zhang
Michael Aaron Brodney
Michael Eric Green
Chakrapani Subramanyam
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20160156(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CU20160156A7 publication Critical patent/CU20160156A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
CUP2016000156A 2014-04-25 2016-10-24 Compuestos de isoquinolinas 2-sustituidas o sus análogos que poseen hasta cinco átomos de carbono sustituidos por nitrógeno,útiles como ligandos de dopamina d1 CU20160156A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461984079P 2014-04-25 2014-04-25
PCT/IB2015/052604 WO2015162516A1 (fr) 2014-04-25 2015-04-09 Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1

Publications (1)

Publication Number Publication Date
CU20160156A7 true CU20160156A7 (es) 2017-02-02

Family

ID=53276921

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2016000156A CU20160156A7 (es) 2014-04-25 2016-10-24 Compuestos de isoquinolinas 2-sustituidas o sus análogos que poseen hasta cinco átomos de carbono sustituidos por nitrógeno,útiles como ligandos de dopamina d1

Country Status (26)

Country Link
US (2) US9540352B2 (fr)
EP (1) EP3134404A1 (fr)
JP (1) JP6239149B2 (fr)
KR (1) KR20160142402A (fr)
CN (1) CN107074843A (fr)
AP (1) AP2016009512A0 (fr)
AU (1) AU2015249497A1 (fr)
BR (1) BR112016023740A2 (fr)
CA (1) CA2946475A1 (fr)
CL (1) CL2016002677A1 (fr)
CR (1) CR20160494A (fr)
CU (1) CU20160156A7 (fr)
DO (1) DOP2016000289A (fr)
EA (1) EA201691788A1 (fr)
IL (1) IL248132A0 (fr)
MA (1) MA39914A (fr)
MD (1) MD20160109A2 (fr)
MX (1) MX2016013969A (fr)
NI (1) NI201600161A (fr)
PE (1) PE20170009A1 (fr)
PH (1) PH12016501993A1 (fr)
SG (1) SG11201608468TA (fr)
SV (1) SV2016005305A (fr)
TN (1) TN2016000447A1 (fr)
TW (1) TWI561517B (fr)
WO (1) WO2015162516A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3134405B1 (fr) 2014-04-25 2019-08-28 Pfizer Inc Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine
CR20160493A (es) * 2014-04-25 2016-12-16 Pfizer Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CA2946990A1 (fr) 2014-04-28 2015-11-05 Pfizer Inc. Composes heterocycliques et leur utilisation comme ligands des recepteurs d1 de la dopamine
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
PT3562821T (pt) 2016-12-28 2021-03-03 Minoryx Therapeutics S L Compostos de isoquinolina, métodos para a sua preparação e utilizações terapêuticas dos mesmos em condições associadas à alteração da atividade da beta-galactosidade
EP3870292A4 (fr) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York Combinaison d'un inhibiteur de réabsorption spécifique de la sérotonine et d'un agoniste partiel du récepteur de la sérotonine 1a pour réduire la dyskinésie induite par l-dopa
KR102783635B1 (ko) 2021-04-19 2025-03-18 유니버시떼 드 몬트리얼 피리도[3,2-d]피리미딘 화합물, 증식성 질환을 치료하기 위한 이의 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63145272A (ja) * 1986-12-09 1988-06-17 Morishita Seiyaku Kk ４，５−ジヒドロ−６−（４−置換フエニル）−３（２ｈ）−ピリダジノン誘導体
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2004510712A (ja) 2000-09-22 2004-04-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド オクタヒドロ−インドリジンおよびキノリジンおよびヘキサヒドロ−ピロリジン
CA2615420A1 (fr) * 2005-07-15 2007-01-25 4Sc Ag 2-arylbenzothiazoles et leurs utilisations
EP1746096A1 (fr) * 2005-07-15 2007-01-24 4Sc Ag Analogues de 2-arylbenzothiazole utiles comme agents anticancereux
JP2010509392A (ja) * 2006-11-13 2010-03-25 ファイザー・プロダクツ・インク ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
BRPI0922809A2 (pt) * 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
WO2010088177A1 (fr) * 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité d'akt
PH12012501621A1 (en) * 2010-02-11 2012-10-22 Univ Vanderbilt Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
KR20130044381A (ko) * 2010-03-04 2013-05-02 머크 샤프 앤드 돔 코포레이션 카테콜 ｏ－메틸 트랜스퍼라제의 억제제 및 정신병적 장애의 치료에서의 그의 용도
RU2018100142A (ru) * 2010-03-24 2019-02-20 Амитек Терапетикс Солюшинс, Инк. Гетероциклические соединения, эффективные для ингибирования киназы
CN102558147B (zh) 2010-12-23 2014-09-17 江苏先声药物研究有限公司 化合物、制备方法及应用
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
WO2014059185A1 (fr) * 2012-10-12 2014-04-17 Amgen Inc. Composés amino-dihydrothiazine et amino-dioxydo dihydrothiazine en tant qu'antagonistes de bêta-sécrétase et procédés d'utilisation
SG11201502763VA (en) 2012-11-08 2015-05-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
JP5823657B1 (ja) 2012-11-08 2015-11-25 ファイザー・インク ドーパミンｄ１リガンドとしての複素芳香族化合物
CN102964340B (zh) * 2012-12-12 2015-10-07 中国药科大学 一类治疗阿尔茨海默病的选择性多巴胺d1受体激动剂
JP6026024B2 (ja) 2013-06-27 2016-11-16 ファイザー・インク 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
EP3134405B1 (fr) 2014-04-25 2019-08-28 Pfizer Inc Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine
CR20160493A (es) 2014-04-25 2016-12-16 Pfizer Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
CA2946990A1 (fr) 2014-04-28 2015-11-05 Pfizer Inc. Composes heterocycliques et leur utilisation comme ligands des recepteurs d1 de la dopamine

Also Published As

Publication number Publication date
MA39914A (fr) 2017-03-01
CR20160494A (es) 2016-12-20
US20160200711A1 (en) 2016-07-14
DOP2016000289A (es) 2017-02-15
EP3134404A1 (fr) 2017-03-01
TN2016000447A1 (en) 2018-04-04
MX2016013969A (es) 2017-01-11
NI201600161A (es) 2016-11-25
KR20160142402A (ko) 2016-12-12
EA201691788A1 (ru) 2017-03-31
US9850232B2 (en) 2017-12-26
JP2017513881A (ja) 2017-06-01
TW201604188A (zh) 2016-02-01
BR112016023740A2 (pt) 2017-08-15
US9540352B2 (en) 2017-01-10
PH12016501993A1 (en) 2017-01-09
AP2016009512A0 (en) 2016-10-31
CA2946475A1 (fr) 2015-10-29
CL2016002677A1 (es) 2017-02-10
SV2016005305A (es) 2017-07-19
AU2015249497A1 (en) 2016-10-20
WO2015162516A1 (fr) 2015-10-29
IL248132A0 (en) 2016-11-30
CN107074843A (zh) 2017-08-18
MD20160109A2 (ro) 2017-04-30
PE20170009A1 (es) 2017-03-17
SG11201608468TA (en) 2016-11-29
JP6239149B2 (ja) 2017-11-29
US20150307494A1 (en) 2015-10-29
TWI561517B (en) 2016-12-11

Similar Documents

Publication Publication Date Title
CU20160156A7 (es) Compuestos de isoquinolinas 2-sustituidas o sus análogos que poseen hasta cinco átomos de carbono sustituidos por nitrógeno,útiles como ligandos de dopamina d1
DOP2016000290A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
MX2015017169A (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina.
CL2012003178A1 (es) Compuestos derivados de heterociclos nitrogenados insaturados o sus sales farmaceuticamente aceptables, como inhibidores de pde10; composicion farmaceutica que los comprende; y su uso para el tratamiento de enfermedades tales como psicosis, enfermedad de parkinson, depresion, trastornos del humor y demencia.
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CL2015000096A1 (es) Compuestos derivados de 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos, inhibidores de fosfodiestearasa 2 y/o 10; composicion farmaceutica; y su uso para prevencion o tratamiento de enfermedades del sistema nervioso, como deficiencia cognitiva, demencia, trastornos de ansiedad, enf. de alzheimer, enf. de parkinson, otros
CL2013003731A1 (es) Compuestos derivados de carboxamida; composición farmacéutica que los comprende, y su uso como inhibidores de la fosfodiesterasa tipo 10a (pde10a) para el tratamiento de trastornos del snc, esquizofrenia, disfunción cognitiva relacionada con la esquizofrenia, trastornos bipolares, depresión, disfunción cognitiva, alteraciones cognitivas, trastornos del comportamiento asociados a la enfermedad de alzheimer, obesidad, enfermedad de huntington y ansiedad.
AR085219A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
UY36218A (es) “derivados de piridina como moduladores alostéricos positivos del receptor muscarínico m1”
UY35129A (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
CL2015000559A1 (es) Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras.
UY37947A (es) Amidas de imidazopiridina sustituidas y su uso
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
BR112016017816A8 (pt) derivados de etinila, seus usos, e composição farmacêutica
DOP2015000295A (es) Composiciones farmacéuticas de triazolopiridinas sustituidas, metodos para prepararlas y sus usos
IN2013MU03838A (fr)